Open ‐label study with the monoamine stabilizer (‐)‐OSU6162 in myalgic encephalomyelitis/chronic fatigue syndrome

Conclusions( ‐)‐OSU6162 is well tolerated in ME/CFS patients and shows promise as a novel treatment to mitigate fatigue and improve mood and health‐related quality of life in ME/CFS. Obviously, the present results need to be confirmed in future placebo‐controlled double‐blind trials.

https://onlinelibrary.wiley.com/doi/abs/10.1002/brb3.2040?af=R

Source: Brain and Behavior - February 4, 2021 Category: Neurology Authors: Sara Haghighi, Sara Forsmark, Olof Zachrisson, Arvid Carlsson, Marie K. L. Nilsson, Maria L. Carlsson, Robert C. Schuit, Carl ‐Gerhard Gottfries Tags: ORIGINAL RESEARCH Source Type: research